Ironwood Pharmaceuticals, Inc. (IRWD)
After hours:
| Previous close | 8.31 |
| Open | 8.24 |
| Bid | 8.06 x 200 |
| Ask | 8.14 x 300 |
| Day's range | 8.09 - 8.35 |
| 52-week range | 7.53 - 15.70 |
| Volume | |
| Avg. volume | 4,561,704 |
| Market cap | 1.268B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.45 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.00 |
ZacksOPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
Investor's Business DailyIronwood Pharmaceuticals Ran Up 38% Over Three Months — And Just Lost It All
Shares of Ironwood Pharmaceuticals collapsed Thursday on mixed results for its gastrointestinal drug. The biotech stock erased a 38% gain.
Business WireIronwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON, February 29, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF). SBS-IF, a rare and severe organ failure condition in which patients are dependent on PS, affects an estimat
